Recombinant CD19 (Tafasitamab Biosimilar) 抗体
Research Grade
适用: 人
ELISA
宿主: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
-
- 抗原
- CD19 (Tafasitamab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
- 宿主
-
Mammalian Cells
- Expression System
- Mammalian cells
- 克隆类型
- 单克隆
- 应用范围
- ELISA
- 原理
- Tafasitamab Biosimilar - Anti-CD19 mAb
- 产品特性
- Antibody Type: IgG1-G2-kappa
- 纯化方法
- Recombinant antibody expressed in mammalien cells and purified.
- 质量等级
- Research Grade
- 亚型
- IgG1
-
- 限制
- 仅限研究用
-
- 缓冲液
- PBS pH 7.5
- 储存条件
- -80 °C
- 储存方法
- store at -80°C
-
- 抗原
- CD19 (Tafasitamab Biosimilar)
- 物质类
- Biosimilar
- 背景
-
MOR-00208,MOR-208,XENP-5574,XMP-5574,XmAb-5574,Xmab-CD19
Tafasitamab is a humanized monoclonal antibody that targets CD19. It is used for the treatment of B-cell malignancies. The CD19 surface protein is highly expressed on the surface of B-cells where it enhances B-cell receptor signaling. CD19 is especially expressed in cases of chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL). By its activity, tafasatimab induces the lysis of B-cells. - CAS-编号
- 1422527-84-1
-
You are here:
